Cost-utility analysis of primary HPV testing through home-based self-sampling in comparison to visual inspection using acetic acid for cervical cancer screening in East district, Sikkim, India, 2023 Roopa Hariprasad<sup>1</sup>, Bhavani Shankara Bagepally<sup>2\*\*</sup>, Sajith Kumar<sup>2</sup>, Sangeeta Pradhan<sup>3</sup>, Deepsikka Gurung<sup>3</sup>, Harki Tamang<sup>3</sup>, Arpana Sharma<sup>4</sup>, Tarun Bhatnagar<sup>1\*</sup> <sup>1</sup>School of Public Health, Indian Council Medical Research-National Institute of Epidemiology, Chennai, Tamil Nadu, India <sup>2</sup>Health Technology Assessment Resource Centre, Indian Council Medical Research-National Institute of Epidemiology, Chennai, Tamil Nadu, India <sup>3</sup>Department of Health and Welfare, Government of Sikkim, Gangtok, Sikkim, India <sup>4</sup>Jhpiego - an affiliate of Johns Hopkins University, Gangtok, Sikkim, India \* Corresponding author E-mail: drtarunb@gmail.com (TB) \*\* Co-Corresponding author E-mail: bshankara@gmail.com (BSB) 

## **Abstract**

Introduction

Primary Human Papilloma Virus (HPV) testing offers higher sensitivity and specificity over Visual Inspection using Acetic acid (VIA) in cervical cancer screening. Self-sampling is a promising strategy to boost participation and reduce disparities. However, concerns about the initial costs hinder HPV testing adoption in low and middle-income countries. This study assesses the cost-utility of home-based HPV self-sampling versus VIA for cervical cancer screening in India

#### Methods

A cross-sectional study was conducted in East district, Sikkim, India, comparing the costs and utility outcomes of population-based cervical cancer screening through VIA and primary HPV screening through self-sampling. Cost-related data were collected from April 2021 to March 2022 using the bottom-up micro-costing method, while utility measures were collected prospectively using the EuroQoL-5D-5L questionnaire. The utility values were converted into quality-adjusted life days (QALDs) for an 8-day period. The willingness to pay threshold (WTP) was based on per capita GDP for 2022. If the calculated Incremental Cost-Effectiveness Ratio (ICER) value is lower than the WTP threshold, it signifies that the intervention is cost-effective.

#### **Results**

The study included 95 women in each group of cervical cancer screening with VIA & HPV self-sampling. For eight days, the QALD was found to be 7.977 for the VIA group and 8.0 for the HPV group. The unit cost per woman screened by VIA and

HPV self-testing was ₹1,597 (US\$ 19.2) and ₹1,271(US\$ 15.3), respectively. The ICER was ₹-14,459 (US\$ -173.6), which was much below the WTP threshold for eight QALDs, i.e. ₹ 4,193 (US\$ 50.4).

Conclusion

The findings support HPV self-sampling as a cost-effective alternative to VIA. This informs policymakers and healthcare providers for better resource allocation in cervical cancer screening in Sikkim.

Key words: Cervical cancer screening, Cost-utility analysis, Primary Human Papilloma Virus (HPV) testing, Self-sampling, Visual Inspection using Acetic acid (VIA), EuroQoL-5D-5L

# Introduction

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Cervical cancer ranks as the second most prevalent cancer among women in India. Globocan estimates for 2020 showed 123,907 incident cases, and 77,348 cases succumbed to this disease [1]. In 2016, the Government of India, through the Ministry of Health and Family Welfare, implemented an operational framework with the goal of facilitating the screening and early detection of three preventable cancers: oral, breast, and cervical cancer [2]. Although visual inspection using the acetic acid (VIA) screening method adopted in the program for cervical cancer is evidence-based, there are concerns about the feasibility of its implementation in the field and beneficiary satisfaction [3,4]. Further, Human Papilloma Virus (HPV) testing exhibits higher sensitivity (98%) and specificity (90.6%) than VIA [sensitivity 31.6% and specificity 87.5%][5]. In accordance with World Health Organization's (WHO) recommendation, highincome countries have transitioned from cytology-based screening to primary HPV testing [6]. Research has demonstrated that self-collected samples for HPV testing by women yield comparable results to clinician-collected cervical samples [7,8]. Nevertheless, the implementation of HPV programs in low- and middle-income countries is hindered by the upfront financial burden associated with the adoption of this approach despite its evident advantages over VIA. A systematic review on the cost-effectiveness of all cervical cancer screening methods in low- and middleincome countries revealed that HPV testing through self-sampling is the most costeffective to screen cervical cancer [9]. In the context of India, a single modeling study has examined the cost-effectiveness of three cervical cancer screening strategies: VIA, Pap smear, and HPV DNA [10]. However, to obtain more precise and trustworthy insights, empirical data is required. By utilizing real-world data, we can

gather more reasonable information on the actual costs, effectiveness, and outcomes of cervical cancer prevention strategies when implemented within the Indian healthcare system. Such empirical studies are crucial for enhancing the applicability and validity of findings, empowering policymakers to make well-informed decisions regarding resource allocation for cervical cancer prevention programs in India. Sikkim, a northeastern state in India, has piloted primary HPV screening through selfsampling in the East district to explore the challenges in implementation and planning to scale up to all districts based on the results and availability of funds for the same. In order to consider HPV testing as the primary screening of cervical cancer in the State, a detailed economic analysis using contextual data is needed. An essential factor in evaluating the validity of a new screening program is its ability to demonstrate economic efficiency while also surpassing the physical, psychological, and societal harms stemming from the associated testing and screening procedures. Thus, the current study was planned to assess the cost-utility of home-based HPV self-sampling compared to VIA for cervical cancer screening among women over 30 years in the East district of Sikkim state.

# **Methods**

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

### Study design and setting

We did a cross-sectional study in the East district, Sikkim, India, in which cost-related data was collected retrospectively, while the data for utility measures was collected prospectively. Fig 1 illustrates the study workflow. It includes estimates on the cost of population-based cervical cancer screening through VIA (facility-based) under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD) program and primary HPV screening through self-sampling (home-based)

from a disaggregated societal perspective. This perspective considers costs estimated at both the health provider/system level and the individual level, specifically focusing on the direct expenses borne by women undergoing screening in the form of out-of-pocket payments.

#### Fig 1: Illustration of the Study Work Flow

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Under the NP-NCD, VIA is performed on the eligible population (women aged 30 years and older) by the Community Health Officer (CHO) at Health and Wellness Centres (HWCs). If they are found to be VIA positive, women are referred to PHC for confirmation by Primary Health Centre (PHC) Medical Officer. In the primary HPV screening group, Accredited Social Health Activists (ASHAs) provide the sampling kits to women when they make home visits for either filling Community Based Assessment Checklist (CBAC) or Reproductive and Child Health (RCH) program-related activities. Community Health Workers in India are referred to as ASHAs. They are equipped with Information Education and Communication (IEC) materials, such as charts and videos, which demonstrate the correct procedure for collecting vaginal samples. The woman then collects the sample herself and hands over the sampler kit back to ASHA. The sample is transported to the HPV lab at the district hospital from PHC in an ambulance, which does a weekly visit to District Hospital for transportation of other contingencies like vaccines and medicines. The detailed flow of the screening process in both groups is provided in Fig A of the supplementary file. The activities in both groups are the same once the woman is referred to PHC after screening. Hence, the unit cost is calculated only up to the screening process. Participants' eligibility criteria for calculating the utility values were as follows; women aged 30 years or older who underwent screening using VIA

at HWCs by CHOs, and women aged 30 years or above who underwent screening using HPV self-sampling at home were included in the study. Women who declined to provide consent were not included in the study. The reference period for costing was from April 2021 to March 2022. Considering the mean EuroQol-5 dimension score (SD) of women after cervical cancer screening by VIA to be 0.89 (0.19) and the mean EQ-5D-5L score (SD) of women after HPV self-sampling to be 0.98 (0.19) [11] and power as 85%, alpha as 5% (two-sided), we calculated a sample size of 81 women in each group. Adjusting for a 15% attrition rate, the sample size was calculated to be 95 women in VIA and HPV groups. East district of Sikkim consists of eight PHCs (Two urban and six rural) and forty-three health and wellness centres (HWCs). HPV self-sampling (homebased) is implemented by the state govt in the East district in three PHC catchment areas (two urban and one rural). These HWCs selected for HPV screening do not perform VIA screening anymore. Out of the remaining thirty-two HWCs in the district, the best performing eleven HWCs in terms of number of women screened by VIA were selected.

#### **Data collection-costs**

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

For cost analysis, costing related to human resources, space/building, furniture, equipment, consumables, IEC Material, stationery and overheads for both screening methods was obtained. Utility measures were calculated using EQ-5D-5L scores. Cost analysis in this study was undertaken using a bottom-up approach of microcosting methods. All costs were reported for the reference year 2022 (financial year April 2021 to March 2022). All the resources used in screening for cervical cancer using VIA and HPV were identified, measured and valued. Data on capital and recurrent resources utilised to deliver cervical cancer screening services during the

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

reference year were considered. Costing related to space/building, human resources, furniture, equipment, consumables, IEC Material, stationery and overheads for both screening methods were obtained from records and the data of the same were accessed between 15th January 2023 to 30th April 2023. For estimating the building cost, the current market rental price of a similar space through three key informant interviews was collected for each of the eleven HWCs and the HPV laboratory. The average of the three rental prices was considered. To allocate the cost specifically to the VIA screening activity, an apportioning factor was calculated considering the working time dedicated to VIA screening in a year relative to the total working hours of the healthcare facility. To estimate the human resources cost, the investigator interviewed the study participants and healthcare persons using a structured questionnaire. The information related to salary/wages, perks and time spent on each of the activities of screening were collected. The human resources costs associated with screening were calculated using the apportioning factor derived from the time spent on activities. The consumable cost was assessed using the cost, quantity and procurement date of consumables procured during the reference period for VIA and HPV tests by the state central procurement division. The details were obtained from their stock register and accounts division. For women screened by VIA, the Out of Pocket Expenditure (OOPE) accounted for direct costs associated with transportation to the facility, as well as any food expenses incurred during the screening period for both the women and their attendants, if accompanied. However, in the HPV group, it was not applicable as screening took place at home. The cost of overheads like water, maintenance, the electricity of HWCs and HPV testing lab was obtained at the facility level. The total annual cost incurred by each group was calculated by summing up

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

the costs associated with various components. Unit cost was calculated by dividing the total cost of screening by the number of individuals screened in each group as unit cost per woman screened by VIA and unit cost per woman screened by HPV self-sampling **Data collection-utility** EQ-5D-5L questionnaire was used for the personal interview [12]. Permission to use the paper, telephonic, and digital versions has been obtained from the EuroQol office. The questionnaire has five dimensions graded across five levels of problems. The tool comprises a descriptive questionnaire along with a visual analog scale (VAS) to assess perceived problems. These problem levels were assigned numerical codes ranging from 1 to 5, with each state represented by a 5-digit code. The questionnaire encompasses five dimensions, namely mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and investigates five problem levels, including the absence of problems, minor problems, moderate problems, significant problems, and extreme difficulties or inability to perform. EQ-5D-5L was administered to all the Women undergoing cervical cancer screening by VIA at HWCs as well as women undergoing cervical cancer screening at home by HPV self-sampling between the period 15th January 2023 to 30th April 2023. Cervical cancer screening by VIA is performed at HWCs by trained CHOs as a part of the ongoing NP-NCD program. The questionnaire was administered after the screening procedure is complete and before the CHO informs the VIA result to the woman. For women undergoing HPV self-testing at home, it was administered after she collected the sample. Permission from women to contact her telephonically after eight days was taken in the consent form. The EQ-5D-5L questionnaire was administered telephonically on

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

the 8th day of screening, and the status of symptoms was collected as per the satisfaction questionnaire. Data analysis Scoring in EQ-5D-5L and calculation of QALD for 8 eight days The EO-5D-5L questionnaire responses from study participants were converted into a single index value using India-specific tariff values. This conversion process considered the health-related quality of life (HRQoL) across all five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and assigned a weighted value to each health state. Once the EQ-5D-5L index value was obtained for each individual, it was multiplied by 8 (duration of interest) to calculate the QALDs. This calculation combines the individual's health state utility value with the duration, reflecting the overall quality of life experienced during that period. The EQ-5D-5L VAS scale assesses the self-evaluated quality of life on a scale of 1 (worst imaginable health state) to 100 (best imaginable health state). Median quality of life with interquartile range was reported. **Utility score** An EQ-5D-5L summary index was calculated by deducting the appropriate weights from 1, the value for full health (i.e., state 11111). For estimating the quality-of-life utility values, health states generated from the scoring on the EQ-5D-5L descriptive system was converted into utility scores using the India's value set [13] (which is a collection of index values (weights) for all possible EQ-5D-5L states) was used for estimating the utility score. **Incremental Cost-Effectiveness Ratio (ICER)** As per WHO guidance, the Willingness to Pay (WTP) threshold was determined based on the per capita GDP for the year 2022, amounting to ₹ 1,91,288 (US\$ -

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

2297.7) per QALY. Then, for an eight (days period) QALDs, the WTP of ₹ 4193 (US\$ 50.4) was considered. The Incremental Cost-Effectiveness Ratio (ICER) was then computed by dividing the difference in costs (incremental cost) between the two groups by the difference in the OALD8 scores. If the calculated ICER value is lower than the WTP threshold, it signifies that the intervention is cost-effective. **Uncertainty analysis** A one-way sensitivity analysis was conducted to examine the effects of varying the number of individuals screened using both HPV & VIA methods. Additionally, the analysis included adjustments of all cost components with 10% and 25% variations, and the results were graphically presented. Scenario analysis was performed to evaluate the potential impacts of different testing facility settings, including rural or urban locations. Furthermore, the analysis considered the reduction in HPV cost resulting from competitive pricing offered by manufacturers. We also explored the scenarios, where a healthcare provider at the facility conducted HPV testing, as well as the option of self-sampling at the facility. Statistical analysis was done using Epi-info version 7.2.1.0 All the costs are reported both in Indian National Rupees (INR) -₹ and United States Dollar (US\$) (1 US\$ = \$83.2526), (https://www.exchangerates.org.uk/USD-INR-16 08 2023exchange-rate-history.html) **Ethical** approval Study proposal was approved by the Institute Human Ethics Committee of the ICMR-National Institute of Epidemiology, Chennai, India (Reference number: NIE/IHEC/A/202212-02). All the respondents were interviewed after obtaining written informed consent.

# Results

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

The baseline and screening attributes of women (95 in each group) interviewed in the VIA and HPV screening group are provided in Table 1. Both the HPV group and the VIA group were comparable in terms of age distributions, marital status, educational status, parity and age at first intercourse. However, there was a significant disparity in residence patterns, with VIA consisting of a higher proportion (99%) of participants residing in rural areas, while HPV predominantly comprised individuals living in urban regions (84%). There was a notable distinction in occupational profiles that emerged, with a greater proportion of homemakers (70%) observed in the VIA group, while the HPV testing group exhibited a more diverse range of occupations. After screening, it was observed that the VIA group reported a higher prevalence of symptoms (74%) compared to the HPV group (9%). There was a significant difference among the groups regarding time spent on screening. The out-of-pocket expenditure (OOPE) of women in the VIA group ranged from 0 to ₹ 6000 (US\$ 0 to 72.1) with a median of ₹120 (IQR ₹ 60-200) (US\$ 1.4, IQR ), which. Time to reach the facility and OOPE did not apply to the HPV group since the screening was conducted in their homes.

Table 1: Demographic characteristics of screened women in VIA and HPV group

	Women screened by	Women screened by	
	VIA (n=95) HPV (n=95)		
Age (years)			
Mean (SD)	43.6 ( <u>+</u> 9.8)	41.3 (±8.5)	
Range (yrs)	30-65	30-63	

Residence n (%)			
Urban	1 (1)	80 (84)	
Rural	94 (99)	15 (16)	
Education n (%)			
Literate	89 (94)	87 (92)	
Illiterate	6 (6)	8 (8)	
Occupation n (%)			
Home maker	66 (70)	49 (51)	
Others	29 (30)	46 (49)	
Marital status n (%)			
Ever married	87 (91)	88 (92)	
Others	8 (9)	7 (8)	
Age at first intercourse			
<18 years	17 (18)	14 (15)	
18 years and above	78 (82)	81 (85)	
Parity			
[mean (SD)]	2.44 <u>+</u> 1.5	2.05±1.2	
Symptoms after screening			
(any) n (%)			
Present	70 (74)	8 (9)	
Absent	25 (26)	87 (91)	
Time taken to reach the			
facility			
≤1 hour	86 (90)	NA	
More than one hour	9 (10)		

Time spent on the screening		
test		
≤30 min	85 (89)	95 (100)
> 30 min	10 (11)	0
Out of pocket expenditure		
(INR)		
Median {IQR }	120 {60, 200}	NA

Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus, NA: Not

Applicable

The total annual expenditure on screening women for cervical cancer through VIA and HPV DNA tests amounted to ₹5,79,059 (US\$ 6955.4) and ₹28,16,019 (US\$ 33825), respectively. The details of the annual costs for both screening methods are provided in Table 2. The distribution of the total annual costs for VIA and HPV screening revealed that training (33%) and consumables (30%) comprised the largest proportion of overall expenses in the VIA group. Notably, in the HPV group, approximately 40% (₹11,29,706, US\$ 13569.6) of the total cost was allocated to the purchase of consumables, followed by human resources, which accounted for 30% (₹8,55,848 US\$ 10280.1) of the expenditure.

Table 2: Distribution of total annual cost by inputs for VIA and HPV based screening for cervical cancer during the financial year of 2021-22, Sikkim

	Annual cost in VIA group		Annual cost in HPV	
Inputs			group	
	INR	US\$	(INR)	US\$

Unit cost per test	1,597	19.2	1,271	15.3
No of tests	392		2216	
Total cost	5,79,059	6955.4	28,16,019	33825
Overheads	38,562	463.2	1,35,600	1628.8
Training and meetings	1,91,000	2294.2	1,57,125	1887.3
IEC Material	-	-	22,600	271.5
Consumables	1,76,136	2115.7	11,29,706	13569.6
Human resource	1,52,803	1835.4	8,55,848	10280.1
Furniture & Equipment	12,111	145.5	1,60,859	1932.2
Space/Building	8447	101.5	3,54,281	4255.5

Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus, IEC: Information

During the study period, 392 women underwent VIA screening across eleven HWCs.

#### Education & Communication

These HWCs covered a population of 6,031 eligible women, resulting in a screening coverage of 6.5%. In the HPV group, 2,216 women were screened out of the 6,331 eligible women, yielding a screening coverage of 35%. The unit cost per woman screened by VIA and HPV was ₹ 1,597 (US\$ 19.2) and ₹ 1,271 (US\$ 15.3), respectively.

The comparison of EQ-5D-5L index scores of screened women in VIA and HPV groups is tabulated in Table 3. The mean EQ-5D-5L score was significantly higher in the HPV group (1.00±0) than in the VIA group (0.9903±0.02) (p<0.0001). On the eighth day of screening, the EQ-5D-5L scores remained significantly higher in the HPV group (1.000±0) than in the VIA group (0.9972±0.0118) (p=0.02). The overall health score on the day of screening was significantly higher in the HPV group (88.18±5.44) compared to the VIA group (84.4±6.41), (p<0.0001).

Table 3: EQ-5D-5L index scores of screened women in VIA and HPV group

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

EQ-5D-5L		VIA	HPV	p
Utility score (0-1)	Day 1	0.9903 ±0.0210	1.0000 <u>+</u> 0	< 0.0001
(mean score+SD)				
	Day 8	0.9972 <u>+</u> 0.0118	1.0000 <u>+</u> 0	0.02
Visual Analogue Score (1-100)	Day 1	84.4 <u>+</u> 6.41	88.18 <u>+</u> 5.44	< 0.0001
(mean score <u>+</u> SD)	Day 8	89.23 <u>+</u> 3.42	90.75 <u>+</u> 3.66	0.04

Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus

None of the women in the HPV group complained of any deviation from normal in the five dimensions of the EQ-5D-5L. However, in the VIA group, 17% and 7% experienced pain and anxiety, respectively, on day one; on day eight, 3% reported anxiety. (Supplementary Table A) For a duration of 8 days, the QALD was found to be 7.977 for the VIA group and 8 for the HPV group. Hence the ICER was ₹-14,459 (US\$ 173.7). This is much below the WTP threshold for eight days, i.e., ₹ 4,193 (US\$ 50.4). The sensitivity analysis results for changes in the number of women screened using the VIA method is shown in Fig. 2A. As the number of screened women decreases, the ICER increases. When the number of screened women exceeds 549, HPV selftesting ceases to be more cost-effective than VIA. This implies that a screening coverage increase of 40% is required for VIA to be considered cost-effective than HPV self-testing. Fig 2A: Sensitivity analysis: Change in ICER value with variation in the

# number of women screened by VIA

In contrast, Fig. 2B demonstrates the impact of changes in the number of women screened by the HPV self-testing method on the ICER. As the number of women

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

screened by HPV self-testing decreases, the ICER increases. Specifically, if the screened numbers fall below 1,665, HPV self-testing ceases to be cost-effective. However, even with a 25% lowering in screened numbers, the HPV self-testing method remains cost-effective. Fig 2B: Sensitivity analysis: Change in ICER value with variation in the number of women screened by HPV The sensitivity analysis results for VIA screening (Fig. 3A) highlighted that training expenses and consumables had the highest impact on the ICER. Conversely, for HPV screening, consumables and human resources were found to have the greatest impact on the ICER (Fig 3B). ICER was below the WTP threshold for all the listed scenarios listed. (Supplementary Table B) Fig 3A: Sensitivity analysis; Key driving factors of ICER with 10% variation in item cost Fig 3B: Sensitivity analysis; Key driving factors of ICER with 25% variation in item cost **Discussion** The findings of our study indicate that primary HPV screening through self-sampling is a cost-saving approach for cervical cancer screening, compared to the current recommendation of VIA for population-based screening in India. While the total cost of HPV screening may appear higher, the unit cost per test is substantially lower than VIA, primarily due to the higher screening coverage achieved with HPV screening. HPV self-sampling has been widely recognized for its ability to increase participation in cervical cancer screening as it overcomes various barriers; self-sampling

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

effectively encourages more individuals to participate in regular screening programs, especially in low and middle-income countries [14,15]. Existing literature indicates that adopting self-sampling approaches can enhance screening participation among women and potentially lead to cost reductions [16]. According to a meta-analysis of 29 randomized controlled trials, the utilization of cervical cancer screening services was found to be twice as likely among women who underwent self-sampling compared to those who followed standard-of-care screening practices [17]. Women exhibit a preference for self-collection of samples within the convenience of their homes, as opposed to visiting healthcare facilities for screening [18]. It was found that there was a high level of compliance among women who opted for this selfcollection method, with fewer operational challenges encountered during its implementation. Self-sampling presents a distinct opportunity to reach populations that are typically difficult to access, making it one of the most viable strategies for post-pandemic screening[19]. Self-sampling for HPV holds the promise of diminishing disparities in cervical screening participation within specific demographics and extending access to underserved and previously unscreened women [20,21]. Although VIA is known as a low-cost test and is recommended in low- and middleincome countries, the implementation of this subjective test is a major challenge. An Indian randomized controlled trial demonstrated that a single HPV test can effectively decrease the incidence of advanced cervical cancer and associated mortality. In contrast, VIA screening did not exhibit similar benefits in terms of cancer prevention and mortality reduction [22]. The significant hurdle to the widespread implementation of the more precise and efficient HPV screening method arises from the substantial upfront expenses required to establish screening programs.

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

Although cost plays a vital role, it should not be the exclusive factor guiding decisionmaking. It is imperative to consider the well-being of women, along with their overall quality of life and satisfaction [23]. Our study findings also show significant differences in quality of life between women screened by HPV self-sampling who reported higher utility scores and a better quality of life compared to those who underwent VIA. The higher utility scores indicate that women screened through HPV self-sampling experienced better health-related quality of life, potentially due to reduced anxiety, pain and discomfort associated with the self-sampling approach. These results highlight the potential benefits of implementing HPV self-sampling as a preferred screening method, providing women with a more positive screening experience and ultimately contributing to improved health outcomes. Previous studies have evaluated the cost-effectiveness of HPV self-sampling and VIA for cervical cancer screening [10, 24]. However, unlike these model-based studies, our study uniquely utilizes empirical data, marking the first instance of such an approach in India. An earlier model-based study in India that assessed the cost effectiveness of three screening strategies ie. Papanicolaou test, VIA and clinician based primary HPV testing for cervical cancer screening concluded VIA done every 5 years to be cost effective approach [10]. However, the study measured the healthrelated quality of life of cervical cancer patients rather than screened women to calculate the utility values. This approach failed to capture the immediate change in quality of life associated with the screening procedure itself. In addition, the study did not take into account the building cost of VIA screening as they reported data from camp-based approach.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

Another study that evaluated cost effectiveness of same three screening strategies within a large cluster randomized trial from rural India (Legood R et al., 2005). The study dismissed HPV to be a cost-effective method for cervical cancer screening. It is important to note that this study accounted for all the costs in 2002, during which HPV testing was relatively new and prices were high, likely due to reduced competition in the market. Moreover, the study was conducted in a controlled settings of the trial that would vary from 'real life' situations. The ASPIRE randomized controlled trial included a cost-effectiveness study, which determined that community-based self-collected HPV testing is a cost-effective screening strategy [25]. Our study had few limitations. Building costs are typically higher in urban areas compared to rural areas. Differential implementation of HPV testing in urban areas and VIA testing in rural areas could have led to an overestimation of costs associated with the HPV testing strategy and an underestimation of costs associated with the VIA strategy. It is crucial to consider this limitation when interpreting the cost comparisons between the two screening methods. Another limitation of our study originates from the exclusive implementation of HPV screening within the East district of Sikkim [26]. The adoption of HPV screening specifically within urban area in the district has resulted in the inclusion of women who underwent VIA screening solely from rural PHC catchment regions. This specific sampling approach introduces a potential bias in the recruitment of participants, which may in turn limit the generalizability of the study findings. In this study we have leveraged empirical data to evaluate the cost-utility of population-based self-collected HPV testing that is performed at women's homes. The findings of this study provide a robust support for advocating the adoption and

implementation of HPV self-sampling in India. The results indicate that the benefits obtained outweigh the associated costs, establishing it as a cost-effective approach within the provided threshold.. Further research following a similar framework in diverse settings across India is recommended. These studies would contribute to a more comprehensive understanding of the feasibility of HPV self-sampling as a primary screening method in various regional contexts.

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

**REFERENCES:** 1. IARC. Cervix uteri - Globocan 2020. https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf. Published 2021. Accessed [6 Nov 2023] 2. Operational Guidelines. Prevention Screening and Control of Common Non-Communicable Diseases: Hypertension, Diabetes and Common Cancers (Oral, Breast and Cervix) New Delhi: National Health Mission Ministry of Health and Family Welfare Government of India; 2016. Available from: https://main.mohfw.gov.in/sites/default/files/Operational%20Framework%20Managem ent%20of%20Common%20Cancers 1.pdf accessed [29 August 2023]. 3. Shastri SS. Cancer trends and disparities in India: data needs for providing equitable cancer care. Lancet Oncol. 2018;19(10):1260-1261. Mpinga EK and Chastonay P. Patient satisfaction studies and the monitoring of the rightto health: Some thoughts based on a review of the literature. Glob JHealth Sci 2011;3:64-7. 5. Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One. 2010 Oct 28;5(10):e13711. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva. 2020. https://www.who.int/publications/i/item/9789240014107 Accessed [6 Nov 2023]

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

7. Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physiciancollected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol. 2009; 33(6):446-50. 8. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172-83. 9. Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review. Int J Cancer. 2017; 141(3):437-446. 10. Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, et al. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020 Sep 1;15(9):e0238291 11. Korfage IJ, van Ballegooijen M, Wauben B, Looman CW, Habbema JD, Essink-Bot ML. Having a Pap smear, quality of life before and after cervical screening: a questionnaire study. BJOG. 2012;119(8):936-44. 12. EuroQol Research Foundation. EQ-5D-5L User Guide., 2019. Available from: https://euroqol.org/publications/user-guides. 13. Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, et al. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set. Value Health. 2022;25(7):1218-1226.

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

14. Di Gennaro G, Licata F, Trovato A, Bianco A. Does self-sampling for human papilloma virus testing have the potential to increase cervical cancer screening? An updated meta-analysis of observational studies and randomized clinical trials. Front Public Health. 2022;10:1003461. 15. Gupta S, Palmer C, Bik EM, Cardenas JP, Nuñez H, Kraal L, et al. Self-Sampling for Human Papillomavirus Testing: Increased Cervical Cancer Screening Participation and Incorporation in International Screening Programs. Front Public Health. 2018; 6:77. 16. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. EMA Study team. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study); a population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85-94. 17. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Health. 2019;4(3): e001351. 18. Kilfoyle KA, Des Marais AC, Ngo MA, Romocki L, Richman AR, Barclay L, Brewer NT, Rahangdale L, Smith JS. Preference for Human Papillomavirus Self-Collection and Papanicolaou: Survey of Underscreened Women in North Carolina. J Low Genit Tract Dis. 2018;22(4):302-310. 19. Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB. Cervical Cancer Screening Post pandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer. Int J Women's Health. 2021; 13:841-859.

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

20. Levinson KL, Jernigan AM, Flocke SA, Tergas AI, Gunderson CC, Huh WK, et al. Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis. 2016;20(1):47-51 21. Berner AM, Connolly DJ, Pinnell I, Wolton A, MacNaughton A, Challen C, et al. Attitudes of transgender men and non-binary people to cervical screening: a crosssectional mixed-methods study in the UK. Br J Gen Pract. 2021;71(709):e614-e625. 22. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360(14):1385-94. 23. Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg MJ, Leyden W, Huchko MJ, Kuppermann M, Kulasingam S. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA Intern Med. 2019;179(7):867-878. 24. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial-based analysis of the cost per case detected. Int J Cancer. 2005;117(6):981-7. 25. Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, et al. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. BMJ Open. 2018;8(6):e020484.

26. Dhanasekaran K, Tamang H, Pradhan S, Lhamu R, Hariprasad R. Challenges in setting up a primary human papillomavirus-DNA testing facility in a lower and middle income country: lessons learned from a pilot programme. Ecancermedicalscience. 2022; 16:1492.
Supplimentary file:

a. Table A: EQ-5D-5L frequencies and proportions reported by dimensions and level
b. Table B: Comparison of ICER and unit cost for different cervical cancer screening scenarios
c. Fig A: Flow of screening process in HPV and VIA group




Figure 1




Figure 2A




Figure 2B




Figure 3A




Figure 3B